Jan 6, 2009|
No respite in 2009
Cement makers start shutting down plants
Cement companies are having a tough time. Faced with the prospect of shrinking demand, over supply and low utilization levels, many of them have resorted to shutting down some plants especially in the North. For instance, ACC had closed one of its clinker kilns in Himachal Pradesh due to excess piling up of inventory. The Northern markets are facing a problem largely due to the cement imported from Pakistan, which is cheaper than what is produced domestically. Infact, as reported in a leading business daily, the oversupply situation is set to get worse with as much as 7 MT set to make its way into India and the Middle East. Inability to recover from developers after huge credits being given to them has also impacted the cement companies across the country.
The cement sector is expected to witness subdued growth of 7% to 8% in the next two to three years as compared to earlier estimates of 8% to 10%. The revised view is the result of global economic slowdown that has also impacted growth of the domestic economy. From a medium term point of view the sector is likely to garner lower realisations and the same is expected to exert downward pressure on margins apart from increase in costs. However, the prospects of the cement sector for the long term remain intact owing to the need to build up infrastructure to boost economic growth and on account of unfulfilled demand for dwelling units.
Ranbaxy drags down Daiichi
Ranbaxy's promoters may have made a killing by selling their stake to the Japanese drugmaker Daiichi Sankyo, but the same cannot probably be said of the latter. Ranbaxy's tryst with the US FDA has impacted its sales and profits and the same is expected to have an impact on Daiichi too. As reported in a leading business daily, Daiichi is expected to book more than US$ 3.3 bn (300 bn yen) in losses as a result of the fall in the stock price of Ranbaxy ever since its troubles began. This means that Daiichi will be forced to post its first ever loss at the net level and the same has been pegged at 200 bn yen.
Meanwhile, Ranbaxy's woes continue as the company is unable to launch the generic version of GSK Plc's drug 'Imitrex' for which it had reached a litigation settlement deal with the former as there seems to be no signs yet of the issues raised by the US FDA being resolved any time soon. But Ranbaxy's loss is Dr.Reddy's gain and the latter who had also entered into a similar agreement with GSK Plc will stand to gain in the form of higher revenues and profits from this drug.
More heartaches for the global economies in 2009
The world has left 2008 behind it but 2009 is not expected to get any easier. According to Bloomberg, corporate earnings will continue to slump into the first half of 2009 amid the first simultaneous recessions in the US, Japan and Europe since World War II. Besides the US, where the profits of biggies will dip in the first half, resulting in eight straight quarters of declines, the adverse impact will be felt in Europe and Asia too which are battling lower demand for exports and retail goods. Companies are also under tremendous pressure as demand is waning, cash balances are dwindling and bank lending has become tight.
While profits will rise 4.3% for the full year in the US, profits in Europe are expected to decline for all of 2009 and the situation in Asia could worsen as the recession has not fully hit there yet. In the US especially, retail, finance and auto companies may still report losses while software and healthcare companies will see growth in profits. Half of Asia is most likely to be in recession this year as a US$ 700 bn drop in export earnings causes economies in Japan, Hong Kong, Singapore, South Korea and Taiwan to shrink. Thus, companies will really see their mettle tested this year and the focus will be more on curtailing losses and spending.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
Aug 21, 2017
PersonalFN explains the chief factor pushing gold prices up of late.
Aug 21, 2017
One of the hallmarks of successful investing is to look out for companies that have a unique and enduring moat.
Aug 19, 2017
Ever heard of Lindy Effect? Find out how you can use it to pick timeless stocks.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407